Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. by Packer, Milton et al.
January 26, 2021 Circulation. 2021;143:326–336. DOI: 10.1161/CIRCULATIONAHA.120.051783326
Key Words: empagliflozin ◼ heart 
failure ◼ sodium-glucose transporter 2 
inhibitors
Sources of Funding, see page 335
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or 
hospitalization for heart failure in patients with heart failure and a reduced 
ejection fraction, with or without diabetes, but additional data are needed about 
the effect of the drug on inpatient and outpatient events that reflect worsening 
heart failure.
METHODS: We randomly assigned 3730 patients with class II to IV heart 
failure with an ejection fraction of ≤40% to double-blind treatment with 
placebo or empagliflozin (10 mg once daily), in addition to recommended 
treatments for heart failure, for a median of 16 months. We prospectively 
collected information on inpatient and outpatient events reflecting 
worsening heart failure and prespecified their analysis in individual and 
composite end points.
RESULTS: Empagliflozin reduced the combined risk of death, hospitalization 
for heart failure or an emergent/urgent heart failure visit requiring intravenous 
treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; 
hazard ratio [HR], 0.76; 95% CI, 0.67–0.87; P<0.0001). This benefit reached 
statistical significance at 12 days after randomization. Empagliflozin reduced the 
total number of heart failure hospitalizations that required intensive care (HR, 
0.67; 95% CI, 0.50–0.90; P=0.008) and that required a vasopressor or positive 
inotropic drug or mechanical or surgical intervention (HR, 0.64; 95% CI, 0.47–
0.87; P=0.005). As compared with placebo, fewer patients in the empagliflozin 
group reported intensification of diuretics (297 versus 414  [HR, 0.67; 95% CI, 
0.56–0.78; P<0.0001]). Additionally, patients assigned to empagliflozin were 
20% to 40% more likely to experience an improvement in New York Heart 
Association functional class and were 20% to 40% less likely to experience 
worsening of New York Heart Association functional class, with statistically 
significant effects that were apparent 28 days after randomization and 
maintained during long-term follow-up. The risk of any inpatient or outpatient 
worsening heart failure event in the placebo group was high (48.1 per 100 
patient-years of follow-up), and it was reduced by empagliflozin (HR, 0.70; 95% 
CI, 0.63–0.78; P<0.0001).
CONCLUSIONS: In patients with heart failure and a reduced ejection fraction, 
empagliflozin reduced the risk and total number of inpatient and outpatient 
worsening heart failure events, with benefits seen early after initiation of 
treatment and sustained for the duration of double-blind therapy.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT03057977.
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Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitaliza-tions for heart failure in 8 large-scale trials, includ-
ing those that focused on type 2 diabetes, heart failure 
with a reduced ejection fraction, and chronic kidney 
disease.1–8 Although hospitalization for heart failure has 
been regarded as a reliable surrogate of disease pro-
gression in heart failure,9,10 efforts to standardize the 
identification of events by the process of adjudication 
typically exclude many events that are regarded as clini-
cally meaningful by the treating physician.11–14 Further-
more, any benefit on hospitalizations for heart failure 
should not be counterbalanced by an increase in other 
causes of hospitalizations, leading to little overall ben-
efit when the effect on hospitalizations for any reason 
are analyzed.
Importantly, hospitalization for heart failure repre-
sents only a small fraction of a patient’s total life ex-
periences.15,16 If the goal of treatment is to maintain 
clinical stability, an intervention should have a favorable 
impact on other manifestations of worsening heart 
failure, particularly those that occur in an outpatient 
setting.17 These include worsening functional capacity, 
worsening of symptoms that require intensification of 
background therapy (especially diuretics), and the need 
for treatment in an emergent or urgent care setting. 
These outpatient events carry an adverse prognostic 
import comparable to that of a heart failure hospital-
ization.18–21 Several treatments that reduce the risk of 
hospitalizations for heart failure in patients with heart 
failure and a reduced ejection fraction also favorably 
impact outpatient metrics of clinical instability.21–23
Little is known about the effect of SGLT2 inhibitors 
on the broad spectrum of both inpatient and outpatient 
worsening heart failure events, because these were not 
documented in trials with these drugs in type 2 dia-
betes.1–5 The EMPEROR-Reduced  (Empagliflozin Out-
come Trial in Patients With Chronic Heart Failure With 
Reduced Ejection Fraction) trial demonstrated a benefit 
of SGLT2 inhibition with empagliflozin to reduce both 
the risk and rate of heart failure hospitalizations.7 The 
current report expands the findings of the effects on 
the drug on both inpatient and outpatient worsening 
heart failure events.
METHODS
The design and methodology used in the EMPEROR-Reduced 
trial have been described in detail in previous publications.7,24 
The trial was a randomized, double-blind, parallel-group, 
placebo-controlled, and event-driven study. Ethics approval 
was obtained at each study site, and all patients provided 
informed consent to participate in the study; the registration 
identifier at ClinicalTrials.gov is NCT03057977. Data will be 
made available on request in adherence with transparency 
conventions in medical research and through requests to the 
corresponding author. The executive committee of EMPEROR 
has developed a comprehensive analysis plan and numerous 
prespecified analyses, which will be presented in future scien-
tific meetings and publications. At a later point in time, the 
full database will be made available in adherence with the 
transparency policy of the sponsor (available at https://trials.
boehringer-ingelheim.com/transparency_policy.html).
Study Patients
We enrolled men or women with chronic heart failure (New 
York Heart Association [NYHA] functional class II, III, or IV) 
with a left ventricular ejection fraction ≤40%, who were all 
receiving appropriate treatments for heart failure, includ-
ing diuretics, inhibitors of the renin-angiotensin system and 
neprilysin, β-blockers, mineralocorticoid receptor antagonists, 
and when indicated, cardiac devices.
We designed the trial to preferentially enroll patients with 
a left ventricular ejection fraction of ≤30%. To do so, we lim-
ited the number of patients with an ejection fraction >30% 
by requiring them to have a hospitalization for heart failure 
within 12 months or high levels of NT-proBNP (N-terminal 
prohormone B-type natriuretic peptide; ie, ≥1000 pg/ml or 
≥2500 pg/ml in those with an ejection fraction of 31% to 
35% or 36% to 40%, respectively) as compared with ≥600 
pg/ml in those with an ejection fraction of ≤30%. These 




• Empagliflozin reduced the total number of hospi-
talizations for heart failure, including those that 
required intensive care and those that required a 
vasopressor or positive inotropic drug or mechani-
cal or surgical intervention.
• Patients treated with empagliflozin were less likely 
to require intensification of diuretics and were more 
likely to experience improvement (and less likely to 
show deterioration) in New York Heart Association 
functional class in the outpatient setting.
• The effect of empagliflozin to reduce the combined 
risk of death, hospitalization for heart failure, or an 
emergent or urgent heart failure visit was statisti-
cally significant at 12 days after randomization.
What Are the Clinical Implications?
• The effect of empagliflozin to reduce worsening 
heart failure events in both the outpatient and 
inpatient setting reinforces its previously reported 
benefits to reduce the combined risk of cardiovas-
cular death and hospitalization for heart failure and 
to decrease the risk of serious adverse renal events.
• The combined results of EMPEROR-Reduced and 
the DAPA-HF trials support the use of SGLT2 inhibi-
tors as part of standard of care for patients with 
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Patients who fulfilled prespecified inclusion and exclusion 
criteria were randomized, double-blind (in a 1:1 ratio) to 
receive placebo or empagliflozin 10 mg daily, in addition to 
their usual therapy for heart failure. After randomization, all 
appropriate treatments for heart failure or other medical con-
ditions could be initiated or altered at the clinical discretion 
of the investigator in response to changes in each patient’s 
clinical status. Patients were assessed at study visits for major 
outcomes, symptoms and functional capacity related to heart 
failure, changes in medications used for heart failure, vital 
signs, biomarkers reflecting changes in the course of heart 
failure or the action of SGLT2 inhibitors, and adverse events; 
these assessments took place every 2 to 6 months, depend-
ing on the metric and the duration of follow-up. All random-
ized patients were followed for the occurrence of prespecified 
outcomes for the entire duration of the trial, regardless of 
whether the study participants were taking their study medi-
cations or were compliant with study procedures.
Trial End Points
We specified 3 measures as major outcomes to be evaluated 
in a hierarchical manner.
The primary end point was the composite of adjudicated car-
diovascular death or hospitalization for heart failure, analyzed 
as time-to-first-event. The first secondary end point was the 
occurrence of all adjudicated hospitalizations for heart failure 
(including first and recurrent events). The second secondary end 
point was the analysis of the slope of the change in estimated 
glomerular filtration rate during double-blind treatment, which 
was supported by an analysis of a composite of end-stage renal 
events. We planned to enroll ≈3600 patients who were expected 
to experience a target of 841 adjudicated primary end point 
events during a follow-up period of 6 to 36 months.
To ascertain these major outcomes, we prospectively col-
lected information on all deaths, all hospitalizations for any 
reason, and all emergent and urgent outpatient events that 
may reflect worsening heart failure. Hospitalizations were 
classified as cardiovascular or noncardiovascular based on 
the judgment of the investigator. In contrast, a heart failure 
hospitalization was prospectively identified by a clinical-event 
committee in a blinded manner using prespecified criteria. To 
qualify as an adjudicated heart failure hospitalization, patients 
were required to have meaningful worsening of their clini-
cal status and intensification of treatment for heart failure. 
The duration of the in-hospital stay was at least 12 hours; 
if the patient had not received intravenous medications for 
heart failure, the minimum stay of an adjudicated heart fail-
ure hospitalization was 24 hours. Investigators documented 
the clinical course of each hospital admission on a dedicated 
form, including the prescribing of medications and devices 
used to treat episodes of clinical decompensation. The com-
mittee also adjudicated the occurrence of myocardial infarc-
tion, stroke, and transient ischemic attack.
In addition to the adjudication and characterization of hos-
pitalizations for heart failure, at each scheduled study visit, 
patients were prospectively asked about interval events and 
changes in the use of diuretics that reflected the occurrence of 
worsening heart failure since the last visit. Events that were con-
sidered to reflect clinical deterioration included: (1) worsening 
heart failure that required the use of an intravenous drug for 
heart failure in an emergency department; (2) worsening heart 
failure that required the use of an intravenous drug for heart 
failure in an outpatient urgent care setting; (3) intensification 
of daily doses of diuretics for worsening symptoms; and (4) 
worsening NYHA functional class. Events treated in an emer-
gency department, urgent care setting, or during a hospital 
stay shorter than that required for an adjudicated event were 
grouped together. Physicians were not provided any specific 
guidance as to the degree or duration of diuretic intensifica-
tion that would qualify as representing a clinically meaning-
ful change. Ascertainment of these events and measures were 
prospectively collected in the case report form, and their inclu-
sion in analyses of individual and composite end points was 
prespecified before the blind of the trial was broken.
Statistical Analysis
For time-to-first-event analyses, differences between the pla-
cebo and empagliflozin groups were assessed for statistical 
significance using a Cox proportional hazards model, with 
prespecified covariates of age, sex, geographical region, 
diabetes status at baseline, left ventricular ejection fraction, 
and estimated glomerular filtration rate at baseline. For these 
analyses, the assumption of proportional hazards was inves-
tigated, and no violations were observed. For the analysis of 
total (first and repeated) events, between-group differences 
were assessed using a joint frailty model, with cardiovascular 
death (for end points including heart failure events) or all-
cause mortality (for end points including all-cause hospitaliza-
tion) as competing risks, and using covariates that were used 
for time-to-first-event analyses. For the analysis of changes 
in vital signs and laboratory measurements, treatment effects 
were assessed based on changes from baseline using a mixed 
model for repeated measures that included age and baseline 
estimated glomerular filtration rate as linear covariates and 
baseline score by visit, visit by treatment, sex, region, baseline 
left ventricular ejection fraction, individual last projected visit 
based on dates of randomization and trial closure, and base-
line diabetes status as fixed effects. The analysis of changes 
in NT-proBNP was performed on log-transformed data. All P 
values reported are 2-sided, and P values less than 0.05 were 
considered statistically significant.
RESULTS
A total of 3730 patients at 520 centers in 20 countries 
were randomly assigned to placebo (n=1867) or to 
empagliflozin (n=1863). As previously reported,7 the 2 
groups comprised patients with mild, moderate, and se-
vere heart failure, as reflected by left ventricular ejection 
fraction and circulating levels of NT-proBNP, and were 
well-balanced with respect to baseline characteristics.
Effect on Combined Risk of Death or 
Hospitalization
There were 512 patients who died for any reason or 
were hospitalized for heart failure in the placebo group 
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corresponding to annualized rates of 23.3% and 
17.8%, respectively. These differences reflected a 24% 
lower risk as a result of treatment with empagliflozin as 
compared with placebo (hazard ratio [HR], 0.76; 95% 
CI, 0.67–0.87; P<0.0001; Table). There were 674 pa-
tients who died for any reason or were hospitalized for 
a cardiovascular reason in the placebo group and 556 
such patients in the empagliflozin group, corresponding 
to annualized rates of 33.4% and 26.1%, respectively. 
These differences reflected a 22% lower risk as a result 
of treatment with empagliflozin as compared with pla-
cebo (HR, 0.78; 95% CI, 0.70–0.87; P<0.0001). There 
were 860 patients who died or were hospitalized for 
any reason in the placebo group and 743 such patients 
in the empagliflozin group, corresponding to annual-
ized rates of 47.3% and 38.4%, respectively. These dif-
ferences reflected a 19% lower risk as a result of treat-
ment with empagliflozin as compared with placebo 
(HR, 0.81; 95% CI, 0.74–0.90; P<0.0001; Table; Figure 
I in the Data Supplement).
Effect of Empagliflozin on 
Hospitalizations
As compared with the placebo group, patients in the 
empagliflozin group had fewer total (first and recur-
rent) hospitalizations for heart failure (553 versus 388 
[HR, 0.70; 95% CI, 0.58–0.85; P=0.0003]), fewer total 
(first and recurrent) hospitalizations for a cardiovascular 
reason (999 versus 819 [HR, 0.78; 95% CI, 0.67–0.91; 
P<0.0001]), and fewer total (first and recurrent) hospi-
talizations for any reason (1570 versus 1364 [HR, 0.85; 
95% CI, 0.75–0.95; P=0.007]; Table). Adjudicated 
cardiovascular events not related to heart failure were 
uncommon (occurring in 3%) and similar in the 2 treat-
ment groups (Table I in the Data Supplement).
The effect of empagliflozin on total hospitalizations 
for heart failure is further described in Table I in the Data 
Supplement. As compared with placebo, fewer patients 
in the empagliflozin group were hospitalized for heart 
failure once (160 versus 231), hospitalized for heart fail-
ure twice (50 versus 61), and hospitalized for heart fail-
ure ≥3 times (36 versus 50). The effect of empagliflozin 
on first and recurrent hospitalizations for heart failure 
was consistent in 12 prespecified subgroups, except for 
a nominally significant treatment-by-race interaction 
(Figure II in the Data Supplement).
Empagliflozin also reduced the severity of heart 
failure admissions and the frequency of utilization of 
a broad range of interventions used for the manage-
ment of decompensated heart failure. Empagliflozin 
decreased the time to the first heart failure hospital-
ization that required intensive care (HR, 0.65; 95% CI, 
0.50–0.85; P=0.002) and also decreased the total num-
ber of such heart failure admissions (HR, 0.67; 95% CI, 
0.50–0.90; P=0.008; Table; Figure 1). When compared 
with the placebo group, the empagliflozin group ex-
perienced fewer total hospitalizations for heart failure 
that required only oral or intravenous diuretics (219 ver-
sus 293), fewer hospitalizations for heart failure that 
required intravenous vasodilators but no vasopressor 
or positive inotropic agents or mechanical support (36 
versus 54), fewer admissions for heart failure that re-
quired a vasopressor or positive inotropic agent but no 
mechanical support (92 versus 152), and fewer hospi-
talizations for heart failure that required mechanical or 
surgical intervention (24 versus 34; Table I in the Data 
Supplement).
For hospitalizations that required a vasopressor or 
positive inotropic support or mechanical or surgical in-
terventions, empagliflozin not only reduced the time-
to-first-event (HR, 0.75; 95% CI, 0.57–0.98; P=0.03), 
but also decreased the risk of a first or recurrent event 
(HR, 0.64; 95% CI, 0.47–0.87; P=0.005; Table; Fig-
ure 2). When considering all hospitalizations for heart 
failure, the 2 groups were similar with respect to the 
median duration of each admission for heart failure 
(9.0 [interquartile range, 6–15] for placebo versus 8.0 
days [interquartile range, 5–15] for empagliflozin).
Effect of Empagliflozin on Worsening 
Heart Failure Events Other Than 
Hospitalizations
Patients in the empagliflozin group experienced fewer 
emergency department or urgent care visits for wors-
ening heart failure (Table I in the Data Supplement). 
Empagliflozin reduced the time to a first emergent/
urgent care for heart failure (HR, 0.66; 95% CI, 0.53–
0.83; P=0.0004) and decreased the risk of total (first 
or recurrent) emergent/urgent care visits for heart fail-
ure (HR, 0.63; 95% CI, 0.49–0.831; P=0.0004); Table). 
Many of the emergent and urgent heart failure events 
were soon followed by admission to a hospital on the 
same day, but among those that represented stand-
alone events, there were fewer events in the empa-
gliflozin group than in the placebo group (43 and 56 
events, respectively).
When a worsening heart failure event is defined 
as death, hospitalization for heart failure or an emer-
gent or urgent heart failure visit requiring intravenous 
treatment, empagliflozin reduced the risk of a worsen-
ing heart failure event (HR, 0.76. 95% CI, 0.67–0.87; 
P<0.0001; Figure  3). The benefit of empagliflozin on 
this end point first reached statistical significance at 12 
days after randomization, and statistical significance 
was sustained from day 34 onwards (Figure III in the 
Data Supplement).
As compared with placebo, fewer patients in the 
empagliflozin group reported intensification of diuret-
ics since the previous study visit (297 versus 414), and 
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Table. Major Outcomes and Inpatient and Outpatient Worsening Heart Failure Events
Variable
Placebo, % (n=1867) Empagliflozin, % (n=1863)
Hazard ratio








  Time to all-cause mortality or cardiovascular 
hospitalization
674 (36.1) 33.4 556 (29.8) 26.1 0.78 (0.70–0.87) <0.0001
  Time to all-cause mortality or hospitalization for any 
reason
860 (46.1) 47.3 743 (39.9) 38.4 0.81 (0.74–0.90) <0.0001
  Time to first hospitalization for cardiovascular reason 570 (30.5) 28.3 452 (24.3) 21.2 0.75 (0.67–0.85) <0.0001
  Time to first hospitalization for any reason 796 (42.6) 43.8 688 (36.9) 35.6 0.82 (0.74–0.90) <0.0001
  Total (first and recurrent) number of cardiovascular 
hospitalizations
999 — 819 — 0.78 (0.67–0.91) 0.001
  Total (first and recurrent) number of hospitalizations 
for any reason
1570 — 1364 — 0.85 (0.75–0.95) 0.007
  Total hospitalizations requiring intravenous 
vasopressors or positive inotropic drugs
239 — 155 — 0.67 (0.50–0.88) 0.005
Worsening heart failure events
  All-cause mortality or adjudicated hospitalization for 
heart failure
512 (27.4) 23.3 407 (21.8) 17.8 0.76 (0.67–0.87) <0.0001
  Time to first adjudicated hospitalization for heart 
failure
342 (18.3) 15.5 246 (13.2) 10.7 0.69 (0.59–0.81) <0.0001
  Time to first adjudicated hospitalizations for heart 
failure requiring IV vasopressor or positive inotropic 
drugs or mechanical or surgical intervention
120 (6.4) 5.0 91 (4.9) 3.8 0.75 (0.57–0.98) 0.03
  Time to first adjudicated hospitalization for heart 
failure requiring CCU/ICU care
139 (7.3) 5.7 89 (4.8) 3.7 0.65 (0.50–0.85) 0.002
  Total (first and recurrent) number of adjudicated 
hospitalizations for heart failure
553 — 388 — 0.70 (0.58–0.85) 0.0003
  Total adjudicated hospitalizations for heart failure 
requiring IV vasopressor or positive inotropic drugs or 
mechanical intervention
186 — 116 — 0.64 (0.47–0.87) 0.005
  Total adjudicated hospitalizations for heart failure 
requiring CCU/ICU care
171 — 118 — 0.67 (0.50–0.90 0.008
  Time to first investigator-identified hospitalization for 
heart failure
429 (23.0) 20.1 317 (17.0) 14.2 0.71 (0.61–0.82) <0.0001
  Time to first emergency or urgent care visit for 
worsening heart failure requiring IV therapy
185 (9.9) 7.9 126 (6.8) 5.3 0.66 (0.53–0.83) 0.0004
  Total (first and recurrent) emergency or urgent care 
visits for worsening heart failure requiring IV therapy
261 — 184 — 0.63 (0.49–0.81) 0.0004
  Time to first study visit that reported interval 
intensification of diuretics
414 (22.2) 19.4 297 (15.9) 13.2 0.67 (0.58–0.78) <0.0001
  Total (first and recurrent) study visits that reported 
interval intensification of diuretics
564 — 380 — 0.67 (0.57–0.78) <0.0001
  Time to all-cause mortality, hospitalization for heart 
failure or emergent or urgent care for heart failure 
requiring IV therapy
519 (27.8) 23.7 415 (22.3) 18.2 0.76 (0.67–0.87) <0.0001
  Time to all-cause mortality, hospitalization for heart 
failure, emergent or urgent care for heart failure 
requiring IV therapy, or diuretic intensification
727 (38.9) 36.7 555 (29.8) 25.9 0.70 (0.63–0.78) <0.0001
  Time to all-cause mortality, hospitalization for heart 
failure, emergent or urgent care for heart failure 
requiring IV therapy, diuretic intensification, or 
deterioration of NYHA functional class
802 (43.0) 48.1 609 (32.7) 33.8 0.70 (0.63–0.78) <0.0001
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diuretic intensification in the empagliflozin group (380 
versus 564) (Table; Table I in the Data Supplement). Con-
versely, the empagliflozin group had somewhat more pa-
tients (281 versus 246) and more study visits (334 versus 
291) where the dose of diuretics was reported to have 
been reduced. Empagliflozin decreased the time to the 
first study visit that reported diuretic intensification (HR, 
0.67; 95% CI, 0.58–0.78; P<0.0001) as well as the to-
tal number of study visits that reported intensification 
of diuretics since the previous visit (HR, 0.67; 95% CI, 
0.57–0.78; P<0.0001; Table; Figure IV in the Data Sup-
plement).
Figure 1. Total (first and recurrent) adjudicated heart failure hospitalizations requiring admission to cardiac care unit or intensive care unit in in the 
placebo and empagliflozin groups.
Shown are mean cumulative function curves for placebo (shown in red) and for empagliflozin (shown in blue). HR indicates hazard ratio.
Figure 2. Total (first and recurrent) adjudicated hospitalization for heart failure requiring intravenous vasopressor or positive inotropic drug or 
mechanical or surgical intervention in the placebo and empagliflozin groups.
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Additionally, at prespecified study visits, patients in 
the empagliflozin group had a 20% to 40% higher 
odds of experiencing an improvement in NYHA func-
tional class and had a 20% to 40% lower odds of expe-
rience worsening of NYHA functional class. The effect 
of empagliflozin for shifts in NYHA class were apparent 
at every scheduled assessment throughout the first year 
of follow-up; the pattern of benefit was similar whether 
or not worst score imputations were used for patients 
who died or had missing data attributable to being lost 
to follow-up or withdrawal of consent (Figure 4). Sta-
tistical significance for both improvement and deterio-
ration in NYHA class was apparent as early as 28 days 
after randomization and was sustained for 52 weeks.
When a worsening heart failure event is defined as 
death, hospitalization for heart failure, an emergent or 
urgent heart failure visit requiring intravenous treat-
ment, diuretic intensification or deterioration in NYHA 
functional class, a worsening heart failure event oc-
curred in 802 patients in the placebo group, but in only 
609 patients in the empagliflozin group, corresponding 
to annualized rates of 48.1% and 33.8%, respectively 
(HR, 0.70; 95% CI, 0.63–0.78; P<0.0001) (Table). The 
effect of empagliflozin on this composite of inpatient 
and outpatient worsening heart failure events first 
reached statistical significance at 12 days after random-
ization, and statistical significance was sustained from 
day 12 onwards.
Serial changes in laboratory tests and vital signs 
are shown in Figures V to IX in the Data Supplement. 
Empagliflozin produced significant increases in hema-
tocrit and decreases in uric acid, which were apparent 
as early as 4 weeks after randomization and were main-
tained for the first 100 weeks. Patients treated with 
empagliflozin experienced an early and sustained de-
crease in body weight, which averaged <1.0 kg. Treat-
ment with empagliflozin was accompanied by small 
decreases in NT-proBNP after 4 weeks, and the effect 
increased in magnitude over time (Figure VIII in the Data 
Supplement). In contrast, the effects of empagliflozin 
on blood pressure seen after 4 weeks (of approximately 
1–2 mm Hg) waned during prolonged treatment (Figure 
IX in the Data Supplement).
DISCUSSION
In the EMPEROR-Reduced trial, empagliflozin reduced 
the risk of cardiovascular death or hospitalization for 
heart failure, a benefit that was driven primarily by an 
effect of the drug to reduce first and recurrent admis-
sions for worsening heart failure.7 Herein we show that 
this benefit on disease progression is not dependent on 
the definition of this end point or on the identification 
and adjudication of events. The effect of empagliflozin 
was similar whether the analysis focused on cardiovas-
cular death or all-cause mortality, and the benefit of the 
drug was not offset by an increase in events unrelat-
ed to heart failure. Even when the analysis includes all 
deaths and all hospitalizations regardless of cause, em-
pagliflozin’s effect on morbidity and mortality remained 
Figure 3. Time-to-first-event analysis of all-cause mortality, heart failure hospitalization, or emergent/urgent care visit for worsening heart failure 
in the placebo and empagliflozin groups.
Shown are Kaplan-Meier curves for placebo (shown in red) and for empagliflozin (shown in blue). Only emergent and urgent care visits requiring intravenous 




 http://ahajournals.org by on February 15, 2021
Packer et al Empagliflozin on Worsening Heart Failure Events
Circulation. 2021;143:326–336. DOI: 10.1161/CIRCULATIONAHA.120.051783 January 26, 2021 333
ORIGINAL RESEARCH 
ARTICLE
clinically meaningful and highly significant. As expected, 
the magnitude of the benefit on hospitalization declined 
when the focus of the analysis broadened beyond heart 
failure events, decreasing from 30% for total heart 
failure hospitalizations to 22% for total cardiovascular 
hospitalizations to 15% for total hospitalizations for any 
reason. This decline is expected whenever hospitaliza-
tions that are not favorably influenced by a treatment 
are progressively added to the analysis of events in a 
clinical setting where only half of the hospital admis-
sions in patients with a meaningfully reduced ejection 
fraction are related to worsening heart failure.
The effect of empagliflozin to reduce hospitaliza-
tions for heart failure was apparent across a broad 
spectrum of event severity. The drug reduced admis-
sions that were treated only with oral or intravenous 
diuretics as well as hospitalizations that required ther-
apy with intravenous vasopressors or positive inotropic 
agents, and treatment also decreased the risk of hospi-
talizations for heart failure that required intensive care. 
The risk of the latter types of admission was reduced 
by 35% by treatment with the SGLT2 inhibitor. At the 
same time, empagliflozin also led to a 34% decrease in 
the risk of patients seeking emergent or urgent treat-
ment for worsening heart failure that were treated with 
intravenous diuretics. A similar risk reduction in urgent 
outpatient worsening heart failure events was also seen 
with dapagliflozin in a large-scale trial in patients with 
heart failure and a reduced ejection fraction (DAPA-HF 
[Dapagliflozin on Worsening Heart Failure or Cardiovas-
cular Death in Patients With Chronic Heart Failure]).23 
Importantly, the lower risk of hospital admissions was 
not counterbalanced by a longer length of stay when 
patients in the empagliflozin group were hospitalized 
for heart failure.
In addition to these events requiring an acute inter-
vention, treatment with empagliflozin had a meaning-
ful effect on the risk of worsening heart failure events 
in the nonurgent outpatient setting. Patients in the 
empagliflozin group had a 20% to 40% higher odds 
of experiencing an improvement in NYHA functional 
class and had a 20% to 40% lower odds of suffering 
worsening of NYHA functional class. Importantly, these 
benefits were statistically significant at the first visit at 
which NYHA functional class was assessed (ie, after 
only 28 days after randomization). When we identified 
a worsening heart failure event in a manner similar to 
the primary end point of the DAPA-HF trial (eg, death, 
hospitalization for heart failure, or an emergent or ur-
gent heart failure visit requiring intravenous treatment), 
a benefit of empagliflozin on this end point first reached 
statistical significance at 12 days after randomization.
The effect of empagliflozin to prevent a meaningful 
deterioration in functional capacity was paralleled by 
an effect of the drug to reduce the need for intensifica-
tion of diuretic therapy, a benefit that was particularly 
apparent during prolonged treatment. Interestingly, 
the effect of empagliflozin to prevent intensification of 
diuretics was twice as great as the effect of the drug 
to promote decreases in the dose of diuretics. These 
observations are similar to those reported with dapa-
gliflozin in heart failure and a reduced ejection fraction, 
where the SGLT2 inhibitor also reduced the need for 
intensification of diuretic therapy, but had minimal ef-
fects on the average dose of prescribed diuretics over 
the course of double-blind treatment.25 Importantly, 
Figure 4. Odds of improvement or deterioration in NYHA functional class during first 52 weeks as a result of treatment with empagliflozin.
Shown are the odds ratios for empagliflozin vs placebo for improvement in NYHA functional class (top, shown in blue) and for deterioration in NYHA functional class 
(bottom, shown in red). An odds ratio of 1.3 indicates 30% higher odds of improvement, whereas an odds ratio of 0.7 indicates 30% lower odds of deterioration. 
Patients who died, were lost to follow-up, or declined consent were assigned worst rank, but very similar results were seen when the analysis was repeated without 
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when all outpatient and inpatient worsening events are 
considered together, the risk of a worsening heart fail-
ure event per 100 patient-years of follow-up was nearly 
50, indicating that only half of our patients with chronic 
heart failure maintained clinical stability when followed 
for 1 year, even though our cohort comprised patients 
with primarily class II symptoms at the start of follow-
up (Table).
We observed consistent effects of empagliflozin on 
a comprehensive series of measures of clinical stability 
in 12 predefined subgroups. Importantly, concomitant 
treatment with mineralocorticoid receptor antagonists 
and neprilysin inhibitors did not attenuate the response 
to SGLT2 inhibition. In our original publication and in a 
meta-analysis of the DAPA-HF and EMPEROR-Reduced 
trials, we noted a somewhat lesser benefit in patients 
with ejection fraction of 31% to 40% and in patients 
with class III symptoms.7,26 However, it should be noted 
that our patients with an ejection fraction of 31% to 
40% were not representative of a clinical practice co-
hort, in that they could be enrolled in our trial only if 
they had markedly increased levels of natriuretic pep-
tides, and moreover, patients with class III symptoms 
represented only a quarter of the patients in the trial. 
Therefore, it is reassuring that when we repeated our 
subgroup analyses in the current paper, with a focus 
on total heart failure hospitalizations, the treatment-by-
subgroup interaction effects for both ejection fraction 
and NYHA functional class were no longer apparent.
The mechanisms by which empagliflozin exerts these 
broad-based effects to maintain clinical stability remain 
to be defined. Although the early benefits of empa-
gliflozin to prevent clinical deterioration may suggest 
the possibility of a hemodynamic or natriuretic effect, 
the magnitude of such an action appears to be mod-
est and is typically short-lived.27–29 Conventional diuret-
ics typically produce immediate declines in natriuretic 
peptides as well as meaningful and durable changes 
in systolic blood pressure, generally without a change 
in hematocrit. In contrast, the early effect of empa-
gliflozin on natriuretic peptides was very small in our 
trial, although the magnitude increased after months 
of therapy; in contrast, the initial decline in blood pres-
sure waned considerably during the course of double-
blind therapy. This time-dependent pattern suggests 
that changes in natriuretic peptides may have been 
the result of (rather than the determinant) of favorable 
long-term effects of SGLT2 inhibitors on cardiac struc-
ture and function. Similar modest changes in natriuretic 
peptides and systolic blood pressure were reported 
with dapagliflozin in patients with heart failure and a 
reduced ejection fraction in 2 trials.30,31 Finally, empa-
gliflozin produced meaningful and sustained increases 
in hematocrit and decreases in uric acid in our study; 
both have been identified as important determinants 
of the heart failure benefits of these drugs in trials of 
patients with type 2 diabetes.32,33 Both erythrocytosis 
and uric acid lowering may represent biomarkers for 
the effect of SGLT2 inhibitors to promote energy depri-
vation signaling and reduce oxidative stress.34,35
Our findings should be considered in light of certain 
limitations. The median duration of follow-up was 16 
months, which was shorter than many trials of neuro-
hormonal antagonists in heart failure. Although the ef-
fects of SGLT2 inhibitors to reduce heart failure events 
beyond the trial duration has not been established, there 
was no indication that the effects of empagliflozin on 
worsening heart failure events waned during the course 
of the current trial. We prospectively assessed changes 
in the Kansas City Cardiomyopathy Questionnaire in our 
trial, but we did not include changes in this measure 
as a worsening heart failure event, because these are 
not typically recognized as such in clinical practice; fur-
thermore, the effect of empagliflozin on this metric are 
being reported in a separate manuscript. Finally, outpa-
tient events were defined by the investigator and were 
not reviewed or adjudicated. However, it is noteworthy 
that, in the current study, the process of adjudication in 
the current trial did not modify the size of the benefit 
of empagliflozin on heart failure hospitalizations (Table).
In conclusion, in patients with heart failure and a 
reduced ejection fraction, empagliflozin reduced the 
risk of inpatient and outpatient worsening heart failure 
events, benefits that were seen within 12 to 28 days of 
initiation of treatment and were sustained for the dura-
tion of double-blind therapy. The effect of SGLT2 in-
hibitors to maintain clinical stability is akin to that which 
has been reported with β-blockers, mineralocorticoid 
receptor antagonists, and angiotensin receptor neprily-
sin inhibitors, but are seen in patients already receiving 
treatment with these drugs.
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